Search Title by author or title

Evaluation of preliminary effects of laser scleral microporation in normotensive and ocular hypertensive eyes

Poster Details

First Author: S.Shah UK

Co Author(s):    A. Hipsley   R. Ang   M. Jackson   M. Rau   L. Gualdi        

Abstract Details


To evaluate and visual outcomes changes the intraocular pressure in the eye following bilateral Laser Scleral Microporation (LSM) therapy.


Subjects were enrolled in an early feasibility study to evaluate the safety and efficacy of the Laser Scleral Microporation (LSM) in normotensive and ocular hypertensive eyes


An Er:YAG laser was used in 4 quadrants on the sclera to rejuvenate age-related ocular rigidity and improve pliability & biomechanical efficiency of the ciliary muscles in 5 critical zones of anatomical and functional significance. Visual outcomes were assessed using the Early Diabetic Retinopathy Study (EDTRS) logMAR charts and intraocular pressure (IOP) was evaluated using a pneumatic tonometer for up to 3 month postoperatively. Patients aged >40 years who showed loss of accommodative ability and near visual acuity of 20/50 or worse were treated. Patients were grouped by IOP: Group 1) normal IOP (n=12); Group 2) elevated IOP (n=5).


Sensitivity analysis of the differences in accommodation between the “young/healthy” and “old/presbyopic” eye identified the age-related changes that contribute most to symptoms of presbyopia. The FEMA demonstrated the dynamic movements of the ciliary muscle, zonules, lens, sclera, choroid, and vitreous during accommodation. Successful treatment simulations were performed using IOL implantation and LSM therapy in a virtual presbyopic eye. Translation of these treatment simulations into the FEMA demonstrate the behavior of IOLs after implantation, and provide insight for future accommodating IOL development, and demonstrate the mechanism of action for LSM therapy.


The FEM was successfully translated into the FEMA. Virtual surgical and therapeutic simulations of IOL implantation and LSM therapy provide novel insight into their effectiveness to treat presbyopia. The FEM and FEMA also provide novel insight to new technology applications in presbyopia.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented

Back to Poster listing